Lecture and Reception: Making MDMA-Assisted Therapy and Marijuana into Medicines for Posttraumatic Stress Disorder: Legal and Medical Implications
Rick Doblin, PhD
MAPS Founder & Executive Director
Marcela Ot’alora, MA, LPC
Principal Investigator, Boulder Study Site
Saturday Feb. 9, 2013
7:00 pm – 9:30
Lecture and Dessert Reception
Ricketson Law Building
Sturm College of Law, Room 180 University of Denver
About the Research
In MAPSʼ pilot study, 83% of the subjects receiving MDMA-assisted psychotherapy no longer met the criteria for PTSD; these benefits were sustained an average of 3.8 years later. MAPSʼ FDA- approved study treating PTSD with marijuana is now blocked by NIDA and the DEA. MAPS is suing DEA in the 1st Circuit Court of Appeals in an effort to end the government monopoly on the supply of marijuana for use in federally regulated research.
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a not-for-profit research and educational organization that develops medical, legal and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. Founded in 1986, MAPS highest priority is to develop MDMA-assisted psychotherapy into a prescription drug for posttraumatic stress disorder (PTSD). Studies are underway in Charleston, SC and Beer Yaakov, Israel. Studies are about to begin in Boulder, Colorado, and Vancouver, Canada. Studies have been completed in the US and Switzerland.
University of Denver, Denver, CO